Akebia Therapeutics (AKBA) Change in Accured Expenses (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Change in Accured Expenses data on file, last reported at $2.0 million in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at $2.0 million, down 26.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $47.8 million (up 848.48% YoY), and the FY2025 annual result was $48.5 million, up 479.82% from the prior year.
• Change in Accured Expenses retreated to $2.0 million in Q1 2026 per AKBA's latest filing, from $13.9 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $16.0 million in Q2 2025 and troughed at -$26.8 million in Q2 2022.
• A 5-year average of -$602235.3 and a median of $2.8 million in 2025 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2023 and 2025: Change in Accured Expenses sank 440.04% in 2023, then soared 2984.2% in 2025.
• A 5-year view of Change in Accured Expenses shows it stood at -$16.5 million in 2022, then surged by 122.55% to $3.7 million in 2023, then soared by 31.26% to $4.9 million in 2024, then jumped by 185.7% to $13.9 million in 2025, then tumbled by 85.39% to $2.0 million in 2026.
• Business Quant data shows AKBA's Change in Accured Expenses at $2.0 million in Q1 2026, $13.9 million in Q4 2025, and $15.8 million in Q3 2025.